drugset
drugset / Trial / NCT01416441

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441 ↗

Phase 3 Completed 170 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.

Timeline

Start
2011-10-19
Primary completion
2014-03-13
Completion
2014-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 52.5 mg Oral
Subject Aripiprazole Other / unclassified 77.5 mg Oral
Subject Aripiprazole Other / unclassified 110 mg Oral

Indications

Tourette syndrome